Citadel Advisors
SLN

Citadel Advisors’s Silence Therapeutics SLN Stock Holding History

Citadel Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.51M Buy
1,234,807
+990,746
+406% +$5.45M ﹤0.01% 3919
2025
Q4 		$1.48M Buy
244,061
+222,556
+1,035% +$1.42M ﹤0.01% 6536
2025
Q3 		$112K Buy
+21,505
New +$119K ﹤0.01% 11766
2025
Q2 		– Sell
-62,441
Closed -$176K – 14852
2025
Q1 		$176K Sell
62,441
-220,296
-78% -$1.08M ﹤0.01% 10633
2024
Q4 		$1.95M Sell
282,737
-153,960
-35% -$1.99M ﹤0.01% 5688
2024
Q3 		$7.94M Buy
436,697
+319,937
+274% +$5.95M ﹤0.01% 3257
2024
Q2 		$2.22M Buy
116,760
+74,078
+174% +$1.58M ﹤0.01% 5121
2024
Q1 		$922K Buy
42,682
+20,945
+96% +$455K ﹤0.01% 7086
2023
Q4 		$378K Buy
+21,737
New +$244K ﹤0.01% 8688
2022
Q4 		– Sell
-22,851
Closed -$226K – 15406
2022
Q3 		$226K Buy
22,851
+11,410
+100% +$120K ﹤0.01% 10157
2022
Q2 		$136K Buy
+11,441
New +$139K ﹤0.01% 11079

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors's SLN Position: Q1 2026 in Review

Citadel Advisors increased its Silence Therapeutics (SLN) stake by 406% in Q1 2026, buying an estimated $5.45M and bringing the position to 1,234,807 shares worth $6.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3919.

Citadel Advisors first reported a position in SLN in Q2 2022 and has held it in 11 quarters since. The position peaked at $7.94M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Citadel Advisors held 1,234,807 shares of Silence Therapeutics worth $6.51M as of Q1 2026.
  • Citadel Advisors bought 990,746 Silence Therapeutics shares in Q1 2026, an estimated $5.45M.
  • Silence Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3919 holding.
  • Citadel Advisors first reported a position in Silence Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Citadel Advisors's Silence Therapeutics position peaked at $7.94M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.